Is Sermorelin Legal in Missouri?

The Short Answer: Sermorelin Is Legal in Missouri With a Prescription

Sermorelin is not a controlled substance, and no Missouri statute bans it. A licensed clinician can prescribe it, and a properly licensed 503A compounding pharmacy can prepare and dispense it to a specific patient. The wrinkle is a 2020 FDA administrative action that removed Sermorelin from the list of bulk drug substances that compounding pharmacies may use without question, which means the pharmacy and prescriber must operate carefully within specific legal channels.

Federal law governs compounding more than state law does in this space. Missouri state pharmacy rules add a layer of oversight but do not independently prohibit Sermorelin. Patients who obtain Sermorelin through a valid prescription from a licensed provider, filled at a licensed pharmacy, are on solid legal ground.

What "Legal" Actually Means for a Compounded Peptide

The word "legal" covers several distinct questions that are worth separating:

1. Is Sermorelin a scheduled controlled substance? No.
2. Can a physician prescribe it? Yes, under the Medical Practice Act.
3. Can a compounding pharmacy make it? Yes, through specific 503A channels.
4. Can it be sold commercially as a finished drug product? No. FDA never approved a replacement after Geref (sermorelin acetate) was withdrawn from the market in 2008.

Each question has its own regulatory answer, and conflating them creates confusion. The rest of this article works through each layer.

FDA Framework: Why the Bulk Drug Substance List Matters

The FDA does not directly regulate the practice of medicine, but it does regulate the drug substances that compounding pharmacies purchase in bulk to make individualized preparations. Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) allows a licensed pharmacist to compound a drug for an identified individual patient based on a valid prescription, provided the drug substance used appears on the FDA's 503A bulk drug substance list or meets certain other criteria. [1]

The 2020 FDA Removal of Sermorelin

In May 2020, the FDA published a final rule removing Sermorelin (along with several other substances) from the 503A bulk drug substances list, citing insufficient evidence of clinical use and safety when compounded. [2] This was not a ban on prescribing Sermorelin. It was an administrative reclassification that placed compounding pharmacies in a more complicated position.

After removal, a 503A pharmacy that continues to compound Sermorelin does so under what the FDA calls "Category 2" status: the substance has been evaluated and is not currently on the approved bulk list. Compounding it anyway could expose the pharmacy to FDA enforcement. This is the central legal risk in the current framework, and it is one patients and providers must discuss openly.

The 503B Outsourcing Facility Question

Section 503B outsourcing facilities (which compound without individual patient prescriptions, at scale, for healthcare providers) face an even stricter standard. Sermorelin does not appear on the 503B bulk drug substances list either, so 503B facilities have no clear pathway to compound it. [3] Patients receiving Sermorelin should confirm their pharmacy operates as a 503A facility serving their specific prescription, not as a 503B bulk supplier.

What This Means for Real Prescriptions in 2025

Some 503A compounding pharmacies in Missouri and across the country continue to compound Sermorelin for individual patients, relying on the argument that they are responding to a legitimate patient-specific prescription from a licensed practitioner. The FDA has not issued a formal enforcement action against every such pharmacy, but the legal risk is real and not zero. Patients and providers should review current FDA guidance before proceeding. [4]

Missouri State Law: Board of Pharmacy and Medical Practice Act

Missouri does not have a state-level statute that independently bans or schedules Sermorelin. The Missouri Board of Pharmacy regulates compounding pharmacies under Missouri Revised Statutes Chapter 338 and follows the federal 503A/503B framework as a baseline standard. [5] A Missouri-licensed compounding pharmacy must hold the appropriate state license, comply with USP Chapter 795 (non-sterile) or USP Chapter 797 (sterile) standards, and operate under a pharmacist-in-charge.

Missouri Board of Pharmacy Oversight

The Missouri Board of Pharmacy conducts inspections and can discipline pharmacies that compound substances outside the federal bulk list framework. In practice, a Missouri pharmacy caught routinely compounding FDA-non-listed bulk substances without patient-specific prescriptions faces both state disciplinary action and potential federal FDA warning letters. Patients should ask any Missouri-based compounding pharmacy for its current license status and whether it has received any FDA or state board communications regarding its peptide compounding practices.

Missouri Medical Practice Act and Physician Prescribing

Under Missouri's Medical Practice Act (Missouri Revised Statutes Chapter 334), a licensed physician has broad authority to prescribe any legal drug substance for an identified patient, provided the prescribing is within the standard of care and supported by a documented clinical rationale. [6] Off-label prescribing, including prescribing Sermorelin for adult growth hormone deficiency or body composition, is legal and widely practiced.

The Missouri State Medical Board does not maintain a specific list of "approved" peptides. A physician who documents a patient's diagnosis, the clinical rationale for Sermorelin, the risks and benefits discussed, and informed consent is operating within the Medical Practice Act's boundaries.

No Missouri-Specific Scheduling

Missouri's controlled substance schedules mirror the federal DEA schedules with some state-specific additions. Sermorelin does not appear on any Missouri controlled substance schedule. [7] This means a physician does not need a DEA-waiver or special state registration to prescribe it, and a pharmacy does not need a Schedule II-equivalent vault to store it.

Clinical Background: What Sermorelin Is and Why It Is Prescribed

Sermorelin is a synthetic 29-amino-acid analogue of growth hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary gland and stimulates the pulsatile release of endogenous growth hormone (GH). Unlike recombinant human growth hormone (rhGH), Sermorelin acts upstream, preserving the body's own feedback mechanisms. [8]

Approved History and Current Status

The FDA approved Sermorelin acetate (brand name Geref) in 1997 for the diagnosis of GH deficiency and for treatment of growth failure in children with GH deficiency. Serono voluntarily withdrew Geref from the U.S. Market in 2008 for business reasons, not safety reasons. [9] No approved commercial Sermorelin product exists in the U.S. Today. All Sermorelin dispensed to patients in Missouri in 2025 comes from compounding pharmacies.

Evidence Base for Clinical Use

The clinical trial data supporting GH secretagogues in adults includes several relevant studies:

• A randomized controlled trial by Vittone et al. (N=89, 26 weeks) found that Sermorelin acetate 0.03 mg/kg/day administered subcutaneously significantly increased IGF-1 levels and lean body mass compared to placebo (P<0.01). [10]
• A 6-month study by Khorram et al. Published in the Journal of Clinical Endocrinology and Metabolism found that nightly Sermorelin injections in older adults (ages 60-75) increased GH pulse amplitude by 43% and improved slow-wave sleep duration. [11]
• The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults notes that GH secretagogues represent a physiologically rational approach to stimulating endogenous GH secretion, though it stops short of recommending them as first-line therapy absent an approved product. [12]

As the Endocrine Society guideline states directly: "Adults with GHD [growth hormone deficiency] experience improved body composition, quality of life, and metabolic parameters with GH replacement therapy." [12] Sermorelin produces these downstream effects by stimulating the pituitary rather than replacing GH directly.

Typical Dosing in Clinical Practice

Most compounding prescriptions written in Missouri and nationwide specify Sermorelin 200 to 300 micrograms (mcg) administered subcutaneously at bedtime, 5 days per week, for a minimum initial course of 3 to 6 months. Some protocols combine Sermorelin with GHRP-2 or GHRP-6 to amplify GH pulse amplitude, though these combinations introduce additional regulatory considerations for each co-ingredient. Dosing should always be individualized based on IGF-1 monitoring, patient weight, and clinical response.

How to Get Sermorelin in Missouri: A Practical Walkthrough

Getting Sermorelin legally in Missouri requires three things: a qualifying diagnosis or clinical indication, a prescription from a licensed provider, and a licensed 503A compounding pharmacy that currently fills Sermorelin prescriptions.

Step 1: Establish a Clinical Indication

A provider will typically order baseline labs before prescribing Sermorelin. The standard workup includes serum IGF-1, a comprehensive metabolic panel, a complete blood count, total and free testosterone (for male patients), and a thyroid panel. Low-normal or below-normal IGF-1 combined with symptoms of GH deficiency (fatigue, decreased muscle mass, increased visceral fat, poor sleep quality) constitutes a reasonable clinical basis for a trial.

Formal adult GH deficiency diagnosis by the Endocrine Society criteria requires provocative GH stimulation testing (insulin tolerance test or glucagon stimulation test) with a peak GH response below 3 ng/mL to 11 ng/mL, depending on BMI. [12] Off-label prescribing for age-related GH decline does not require a formal stimulation test, but the clinical rationale should be documented.

Step 2: Find a Licensed Provider in Missouri

Patients have several options:

• Endocrinologist or internist: Can order full diagnostic workup and prescribe if indicated.
• Anti-aging or functional medicine physician: Many Missouri-licensed functional medicine MDs prescribe GH secretagogues as part of broader hormone optimization protocols.
• Licensed telehealth platform: Missouri participates in the Interstate Medical Licensure Compact, allowing out-of-state physicians licensed in compact member states to see Missouri patients via telehealth. [13] A provider must hold either a Missouri license or an IMLC license to prescribe.

The telehealth pathway is the most common route in 2025. A licensed platform with Missouri-compliant prescribers can complete a medical intake, review labs, issue a prescription, and coordinate pharmacy fulfillment without the patient leaving home.

Step 3: Use a Licensed 503A Compounding Pharmacy

Ask the pharmacy directly:

• Are you licensed by the Missouri Board of Pharmacy?
• Are you a 503A facility (patient-specific compounding) or a 503B outsourcing facility?
• Do you currently compound Sermorelin, and what is your current regulatory standing?
• Have you received any FDA warning letters or untitled letters regarding peptide compounding?

A legitimate compounding pharmacy will answer these questions without hesitation. Avoid any source that sells Sermorelin without requiring a prescription, ships internationally without prescription verification, or labels it "for research use only" while marketing it for human injection. That is illegal product.

Gray Areas and Risks Patients Should Know

Regulatory gray areas exist in this space and deserve plain language.

The FDA Enforcement Discretion Question

The FDA has historically exercised "enforcement discretion" for certain compounded substances, meaning it has not acted aggressively against every compounding pharmacy that compounds a non-listed substance for a specific patient. This discretion is not a legal right. It can change without notice. A patient receiving Sermorelin from a 503A pharmacy that is relying on this discretion should understand they are in a lawful zone that is closer to the edge of the regulatory boundary than a pharmacy compounding, say, a testosterone cream.

"Research Chemical" Sermorelin Is Not Legal for Human Use

A meaningful portion of Sermorelin available online is sold as a "research chemical" with no prescription required. This product is not FDA-regulated, is not tested for sterility or potency, and is not manufactured under pharmaceutical-grade conditions. Injecting it carries risk of infection, incorrect dosing, and contamination. Purchasing it for personal injection is not legal under the FD&C Act regardless of what the vendor claims. [14]

No Missouri-Specific Loophole

Some online sources suggest that state-level "right to try" laws or medical freedom statutes create an independent pathway for peptides outside the FDA framework. Missouri's Right to Try Act (RSMo 191.480) applies specifically to investigational drugs for terminally ill patients and does not create a general exemption for compounded peptides like Sermorelin. [15] No Missouri law creates an independent pathway that bypasses the federal 503A framework.

What the Regulatory Picture Looks Like Going Forward

The FDA's posture on compounded peptides has tightened since 2019, and there is no public signal suggesting Sermorelin will be re-added to the 503A bulk list in the near term. The agency's broader scrutiny of "difficult to compound" drugs and bulk peptide substances suggests continued enforcement pressure on pharmacies that compound non-listed substances without strong individualized patient documentation.

Physicians and pharmacies operating in good faith with proper documentation, individual patient prescriptions, and rigorous pharmacy quality standards have the strongest legal position. Patients who work with licensed providers, get labs, receive a written diagnosis, and use a licensed 503A pharmacy are following the pathway the law provides.

Missouri's own regulatory infrastructure does not add barriers beyond the federal framework, which is straightforward: prescription from a licensed provider, dispensed by a licensed pharmacy, for an identified patient with a documented clinical need.